Rx Diet Drug Sales Still Paltry
According to the popular stock advisory service The Motley Fool, Qsymia’s sales have been minuscule since its launch in Sept. 2012. VIVUS’ revenue from the drug in Q2 2013 was $5.5 million compared to $4.1 million in Q1 2013. At the same time, the company has reported a net loss of $55.5 million, which is […]
Rx Diet Drug Sales Still Paltry Read More »